Overview
Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D. Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. Active against most Gram-positive bacteria and some Gram-negative organisms, Gramicidin D is used primarily as a topical antibiotic and is also found in Polysporin ophthalmic solution.
Indication
For treatment of skin lesions, surface wounds and eye infections.
Associated Conditions
- Allergic Conjunctivitis (AC)
- Allergic Skin Reaction
- Blepharoconjunctivitis
- Conjunctivitis
- Conjunctivitis infective
- Episcleritis
- External ear inflammation
- Eye and eyelid infections
- Inflammatory Skin Disease
- Iridocyclitis
- Keratitis
- Ocular Inflammation
- Otitis Externa
- Rosacea conjunctivitis
- Scleritis
- Seborrhoea of the External Ear
- Stye
- Ulcerative keratitis
- Bacterial blepharitis
- Infected eczema of the Eyelid
- Superficial ocular infections
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| A-S Medication Solutions | 50090-0247 | OPHTHALMIC | 0.025 mg in 1 mL | 8/2/2022 | |
| Dispensing Solutions, Inc. | 55045-1194 | OPHTHALMIC | 0.025 mg in 1 mL | 11/7/2011 | |
| Bausch & Lomb Incorporated | 24208-790 | OPHTHALMIC | 0.025 mg in 1 mL | 8/2/2022 | |
| Physicians Total Care, Inc. | 54868-6253 | OPHTHALMIC | 0.025 mg in 1 mL | 5/4/2011 | |
| Rebel Distributors Corp | 21695-528 | OPHTHALMIC | 0.025 mg in 1 mL | 2/22/2007 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| SWISSCORT CREAM | N/A | N/A | N/A | 8/31/1982 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Sofradex Ear Drops | 157804 | Medicine | A | 12/12/2008 | |
| Kenacomb Otic Ointment tube | 19201 | Medicine | A | 9/30/1991 | |
| OTODEX EAR DROPS dexamethasone (as sodium metasulfobenzoate) framycetin sulfate gramicidin 8 mL bottle | 43840 | Pharmaco Australia Ltd | Medicine | A | 4/1/1993 |
| OTOCOMB Otic ear drops bottle | 56477 | Medicine | A | 8/7/1996 | |
| SOFRADEX EAR DROPS dexamethasone (as sodium metasulfobenzoate) framycetin sulfate gramicidin 8 mL bottle | 13539 | Pharmaco Australia Ltd | Medicine | A | 8/30/1991 |
| Kenacomb Otic ear drops bottle | 19200 | Medicine | A | 9/30/1991 | |
| Kenacomb Ointment tube | 19197 | Medicine | A | 9/30/1991 | |
| OTOCOMB Otic ointment tube | 56460 | Medicine | A | 8/7/1996 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| LIDOSPORIN CREAM | warner-lambert canada inc. | 02230842 | Cream - Topical | 0.25 MG / G | 7/8/1998 |
| LIDOSPORIN CREAM | glaxo wellcome inc. | 01966006 | Cream - Topical | 0.25 MG / G | 12/31/1971 |
| ANTIBIOTIC CREAM | cellchem pharmaceuticals inc. | 02311844 | Cream - Topical | 0.25 MG / G | 12/23/2009 |
| TRIPLE ANTIBIOTIC OINTMENT | cellchem pharmaceuticals inc. | 02297949 | Ointment - Topical | 0.25 MG / G | 12/23/2009 |
| POLYSPORIN EYE AND EAR DROPS STERILE | johnson & johnson inc | 02239156 | Drops - Otic
,
Ophthalmic | 0.025 MG / ML | 2/12/2000 |
| OPTIMYXIN PLUS | euro-pharm international canada inc | 00807435 | Solution - Ophthalmic
,
Otic | 0.025 MG / ML | 12/31/1989 |
| SANDOZ OPTICORT | 02247920 | Solution - Otic
,
Ophthalmic | 0.05 MG / ML | 1/16/2004 | |
| TEVA-TRIACOMB | teva canada limited | 00550507 | Cream - Topical | 0.25 MG / G | 12/31/1992 |
| TRIPLE ANTIBIOTIC OINTMENT | melaleuca of canada inc. | 02088339 | Ointment - Topical | .25 MG / G | 12/31/1994 |
| SOFRACORT STERILE EAR/EYE DROPS | hoechst roussel canada inc. | 01987712 | Drops - Topical | 0.05 MG / ML | 12/31/1966 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| OFTALMOWELL COLIRIO EN SOLUCIÓN | Teofarma S.R.L. | 45030 | COLIRIO EN SOLUCIÓN | Medicamento Sujeto A Prescripción Médica | Commercialized |
| MIDACINA POMADA | Laboratorio De Especialidades Nacionales S.A. | 53744 | POMADA | Medicamento Sujeto A Prescripción Médica | Commercialized |
| FLODERMOL POMADA | Laboratorios Ern S.A. | 48394 | POMADA | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.